Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema

Intravitreal application of triamcinolone and bevacizumab in Coats' disease with macular edema to improve visual outcome. Testing of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography, fluorescein angiography, 30A degrees perimetry, and full-field electroretinography were performed at initial and follow-up visits. Medical treatment consisted of intravitreal injection of 1.25 mg bevazicumab and 1.25 mg triamcinolone, followed by intravitreal injections of 1.25 mg bevazicumab at weeks 4 and 10. Follow-up was 87 weeks. Perimetric results, including a temporal absolute scotoma and reduced electroretinographic amplitudes (photopic and scotopic conditions), did not significantly change during the follow-up, but foveal retinal thickness decreased from 505 mu m to 212 mu m, and BCVA increased from 0.3 at baseline to 1.25 and remained stable during subsequent follow-up. Combined intravitreal treatment with bevacizumab and triamcinolone resulted in significant decrease of central retinal thickness and improved visual acuity in this case report. Severe local or systemic side-effects were not observed.